Gene expression signature for the prediction of FOLFIRI response in advanced colorectal cancer patients

被引：0
|
作者：
Del Rio, Maguy
Molina, Franck
Bascoul-Mollevi, Caroline
Copois, Virginie
Bibeau, Frederic
Chalbos, Patrick
Bareil, Corinne
Kramar, Andrew
Salvetat, Nicolas
Fraslon, Caroline
Conseiller, Emmanuel
Granci, Virginie
Leblanc, Benjamin
Pau, Bernard
Martineau, Pierre
Ychou, Marc
机构：
[1] CNRS, Montpellier, France
[2] CRLC Val Aurelle, Montpellier, France
[3] Sanofi Aventis, Vitry Sur Seine, France
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1294
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients
    Dai, Siqi
    Xu, Shuang
    Ye, Yao
    Ding, Kefeng
    FRONTIERS IN GENETICS, 2020, 11
  • [32] Identification of a molecular signature of radiographic response to cetuximab in patients (pts) with advanced colorectal cancer.
    Garrett, C
    Takimoto, C
    Wojtowicz, M
    Burris, H
    Hidalgo, M
    Tan, B
    Krishnamurthi, S
    Basik, M
    Baselga, J
    Mauro, D
    Lee, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 277S - 277S
  • [33] Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer
    Okuyama, Hiroyuki
    Kagawa, Yoshinori
    Masuishi, Toshiki
    Mishima, Saori
    Shirasu, Hiromichi
    Ando, Koji
    Yuki, Satoshi
    Muro, Kei
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Oki, Eiji
    Komatsu, Yoshito
    Tsuji, Akihito
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2025 - 2028
  • [34] Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer
    Hiroyuki Okuyama
    Yoshinori Kagawa
    Toshiki Masuishi
    Saori Mishima
    Hiromichi Shirasu
    Koji Ando
    Satoshi Yuki
    Kei Muro
    Takayuki Yoshino
    Kentaro Yamazaki
    Eiji Oki
    Yoshito Komatsu
    Akihito Tsuji
    International Journal of Clinical Oncology, 2021, 26 : 2025 - 2028
  • [35] Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: The development of a risk prediction tool
    Dranitsaris, George
    Shah, Amil
    Spirovski, Biljana
    Vincent, Mark
    CLINICAL COLORECTAL CANCER, 2007, 6 (05) : 367 - 373
  • [36] Gene expression signature of colorectal carcinogenesis
    Habermann, J. K.
    Paulsen, U.
    Roblick, U.
    Upender, M. B.
    McShane, L.
    Korn, E. L.
    Wangsa, D.
    Duchrow, M.
    Krueger, S.
    Bruch, H. -P.
    Auer, G.
    Ried, T.
    EJC SUPPLEMENTS, 2006, 4 (06): : 52 - 52
  • [37] A Network-Based Gene Expression Signature Informs Prognosis and Treatment for Colorectal Cancer Patients
    Shi, Mingguang
    Beauchamp, R. Daniel
    Zhang, Bing
    PLOS ONE, 2012, 7 (07):
  • [38] ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
    Sveen, Anita
    Agesen, Trude H.
    Nesbakken, Arild
    Meling, Gunn Iren
    Rognum, Torleiv O.
    Liestol, Knut
    Skotheim, Rolf I.
    Lothe, Ragnhild A.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6001 - 6010
  • [39] Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    B Glimelius
    H Garmo
    Å Berglund
    L A Fredriksson
    M Berglund
    H Kohnke
    P Byström
    H Sørbye
    M Wadelius
    The Pharmacogenomics Journal, 2011, 11 : 61 - 71
  • [40] Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
    Glimelius, B.
    Garmo, H.
    Berglund, A.
    Fredriksson, L. A.
    Berglund, M.
    Kohnke, H.
    Bystrom, P.
    Sorbye, H.
    Wadelius, M.
    PHARMACOGENOMICS JOURNAL, 2011, 11 (01): : 61 - 71
12345